Clinical Trial

Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-28; most recent amendment 2025-09-14.
Trial Details
NCT Number NCT06021483
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions SCLC
Enrollment 300 participants
Start Date 2023-08-16
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-16